Sean Lybrand
Biographic Data
| ID | 8982153 |
|---|---|
| NAME | Sean Lybrand |
| GIVEN NAMES | Sean |
| FAMILY NAME | Lybrand |
| SIGNATURE | LYBRAND S |
| AFFILIATIONS | Amgen Australia Pty Ltd. North Ryde NSW Australia |
| ORCID | 0000-0001-8293-7910 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Accessing the risks
BACKGROUND: Navigating Health Technology Assessment (HTA) processes presents significant challenges for pharmaceutical companies seeking market access in Australia. While previous research has examined HTA decision-making from payer perspectives, pharmaceutical companies' internal decision-making processes remain understudied. OBJECTIVE: To investigate how pharmaceutical companies' market access teams manage uncertainties in the HTA process for m…
Sharing administrative health data with private industry
BACKGROUND: There is good evidence of both community support for sharing public sector administrative health data in the public interest and concern about data security, misuse and loss of control over health information, particularly if private sector organizations are the data recipients. To date, there is little research describing the perspectives of informed community members on private sector use of public health data and, particularly, on …
No prominent works on this page.
Sharing administrative health data with private industry
BACKGROUND: There is good evidence of both community support for sharing public sector administrative health data in the public interest and concern about data security, misuse and loss of control over health information, particularly if private sector organizations are the data recipients. To date, there is little research describing the perspectives of informed community members on private sector use of public health data and, particularly, on …
Accessing the risks
BACKGROUND: Navigating Health Technology Assessment (HTA) processes presents significant challenges for pharmaceutical companies seeking market access in Australia. While previous research has examined HTA decision-making from payer perspectives, pharmaceutical companies' internal decision-making processes remain understudied. OBJECTIVE: To investigate how pharmaceutical companies' market access teams manage uncertainties in the HTA process for m…
Access to medicines (1 work) · Accountability (1 work) · Business (1 work) · Data Analysis and Archiving (1 work) · Data sharing (1 work) · Data-Driven Disease Surveillance (1 work) · Deliberation (1 work) · Health care (1 work) · Jury (1 work) · Law (1 work)